As there is no specific single test to detect M.E., diagnosis is made after other possible known causes for symptoms have been excluded. This should be a positive clinical diagnosis made on a well-characterised constellation of symptoms.
Our Newly diagnosed with M.E./CFS has been endorsed by the National Institute for Health and Care Excellence (NICE) and provides information and advice about the diagnosis, symptoms and management of M.E. There is also guidance to help patients be an active partner in their own care, suggestions for questions to ask GPs, and information about existing guidelines for health professionals. We advise all healthcare professionals who need information on M.E. to begin by downloading and reading this free resource.
Further guidance for GPs in Scotland, building on the SGPS, is provided in our booklet, Managing M.E./CFS: a guide for GPs in Scotland.
The NICE guideline for M.E. and the Scottish Good Practice Statement on M.E. detail the signs and symptoms that characterise M.E., and tests that should be undertaken. Diagnosis should be made after other possible diagnoses have been excluded and the symptoms have persisted for four months in an adult or three months in a child or young person.
The NICE guideline also states that a diagnosis of M.E. “should be reconsidered if none of the following key features are present:
Action for M.E.’s 2014 M.E. Time to deliver survey found that:
Results also indicated that, despite the NICE guideline for M.E. stating that symptoms should be present for four months before diagnosis is made, a significant number of people with M.E. wait much longer, potentially delaying access to specialist care and support.
The prognosis varies, possibly because of sub-types or phenotypes, and different definitions of recovery. A Chief Medical Officer’s report pubished in 2002 concluded that most patients show improvement over time, a substantial number have a fluctuating course of illness with periods of remission and relapse, but that a significant minority become severely ill and permanently disabled.
A review of published studies reported recovery rates of 8–63% (median 40%), with full recovery being rare (5–10% achieving total remission). The prognosis in children and young people is more optimistic.
In February 2015, the Institute of Medicine (IOM) in the US published a landmark report, Beyond M.E./CFS: redefining an illness. It reviewed a substantial body of evidence and makes four key recommendations that could have important implications for the way that M.E. is understood, diagnosed, treated and researched.
The Institute of Medicine report recommends:
Action for M.E.'s response, which was informed by consultation with people affected by M.E., strongly applauds the IOM committee's intention to reinforce and legitimise the serious impact of M.E. As a result of the report, the US Centers for Disease Control began revising the clinical toolkit it publishes for M.E. in April 2015.
Donate now and change a life